Source: Annual Congress 2006 - Aspects of childhood asthma
Disease area: Airway diseases, Paediatric lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Y. Kirk, A. J. Fall, F. J. Hampton, C. J. O‘Brien, M. C. McKean, D. A. Spencer (Newcastle upon Tyne, Middlesbrough, United Kingdom). Cost implications for the introduction of omalizumab in to the management of severe chronic asthma in children. Eur Respir J 2006; 28: Suppl. 50, 2778

Member's Comments

No comment yet.

Related content which might interest you: The use of omalizumab in the management of severe chronic paediatric asthma Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma Year: 2008 Evaluating the efficacy of omalizumab in severe persistent asthma patients Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017 Acute severe asthma: evidence-based management of asthma exacerbations Source: Annual Congress 2008 - PG4 - Paediatric respiratory medicine: wheezing children: asthma and beyond Year: 2008 Combination asthma medication and healthcare use in severe or difficult-to-treat asthma Source: Eur Respir J 2004; 24: Suppl. 48, 131s Year: 2004 Pharmacological strategies for self-management of asthma exacerbations Source: Eur Respir J 2006; 28: 182-199 Year: 2006 Impact of omalizumab in patients with severe asthma Source: Annual Congress 2009 - Aspects of uncontrolled asthma Year: 2009 Real-life long-term omalizumab therapy in children with severe allergic asthma Source: Eur Respir J 2015; 46: 856-859 Year: 2015 Cost analysis for patients with severe asthma receiving omalizumab treatment Source: International Congress 2019 – Clinical aspects of airway diseases Year: 2019 Cost effectiveness of bronchial thermoplasty for treatment of severe asthma patients in spain Source: International Congress 2017 – Does economisation of medicine transfer into benefits for patients? Year: 2017 What matters to people with severe asthma? Exploring add-on asthma medication and outcomes of importance Source: ERJ Open Res, 7 (1) 00497-2020; 10.1183/23120541.00497-2020 Year: 2021 The management of mild asthma Source: Eur Respir J, 57 (4) 2003051; 10.1183/13993003.03051-2020 Year: 2021 Adherence and effectiveness of omalizumab treatment in severe allergic asthma patients: Do the patients like injectable treatment? Source: Annual Congress 2013 –Treatment of asthma Year: 2013 Predictors of effectiveness of omalizumab treatment in patients with severe asthma recruited in a real-life setting Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 Long-term management of persistent asthma in adults Source: ISSN=1025-448x, ISBN=1-904097-26-x, page=376 Year: 2003 A digital therapy for proactively managing exacerbations and delivering therapeutic benefit to patients with moderate to severe asthma Source: International Congress 2019 – Clinical approach to asthma management Year: 2019 Cost effectiveness of omalizumab in Swedish asthma patients Source: Eur Respir J 2006; 28: Suppl. 50, 441s Year: 2006 The ’real-life’ long-term efficacy of omalizumab in severe persistent IgE-mediated allergic asthma in Malta Source: International Congress 2016 – Asthma management Year: 2016 Omalizumab decreases medical resource utilisation in patients with severe allergic asthma in an Italian real-life setting Source: International Congress 2017 – Asthma management Year: 2017 Management of severe asthma in children Source: International Congress 2018 – ME11 Management of severe asthma in children FULLY BOOKED Year: 2018